CYBERJAYA, July 25 (Bernama) — Hematogenix®, the first central oncology laboratory for clinical trials in Malaysia has been officiated on 22 July 2022 by the Minister of Health (MOH), Yang Berhormat (YB) Khairy Jamaluddin. Also present were Ms. Lim Bee Vian, Deputy Chief Executive Officer (Investment Development) of Malaysian Investment Development Authority (MIDA), Dr. Akhmal Yusof, Chief Executive Officer of Clinical Research Malaysia (CRM) and Dr. Hytham Al-Masri, President and Chief Executive Officer of Hematogenix®.
Hematogenix® is a Global Clinical Research Central Laboratory specialising in Oncology/Cancer Research with accreditations from College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), has been in operation globally since 2007 and in Malaysia since June 2021. Hematogenix® is headquartered in Chicago, Illinois with three other branches globally, covering the European market in Manchester, United Kingdom, the China market in Shanghai; and the latest market for Asia Pacific is in Cyberjaya, Malaysia.